185 related articles for article (PubMed ID: 11095463)
1. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients.
Jubault V; Penfornis A; Schillo F; Hoen B; Izembart M; Timsit J; Kazatchkine MD; Gilquin J; Viard JP
J Clin Endocrinol Metab; 2000 Nov; 85(11):4254-7. PubMed ID: 11095463
[TBL] [Abstract][Full Text] [Related]
2. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
3. Graves' disease as an immune reconstitution syndrome in an HIV-1-positive patient commencing effective antiretroviral therapy: case report and literature review.
Knysz B; Bolanowski M; Klimczak M; Gladysz A; Zwolinska K
Viral Immunol; 2006; 19(1):102-7. PubMed ID: 16553555
[TBL] [Abstract][Full Text] [Related]
4. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Solinas P; Mannazzu M; Falchi A; Mura MS; Madeddu G
Clin Endocrinol (Oxf); 2006 Apr; 64(4):375-83. PubMed ID: 16584508
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease.
Chen F; Day SL; Metcalfe RA; Sethi G; Kapembwa MS; Brook MG; Churchill D; de Ruiter A; Robinson S; Lacey CJ; Weetman AP
Medicine (Baltimore); 2005 Mar; 84(2):98-106. PubMed ID: 15758839
[TBL] [Abstract][Full Text] [Related]
6. Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies.
Rubio IG; Perone BH; Silva MN; Knobel M; Medeiros-Neto G
Thyroid; 2005 Feb; 15(2):134-9. PubMed ID: 15753672
[TBL] [Abstract][Full Text] [Related]
7. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
8. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
9. Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction.
French MA; Lewin SR; Dykstra C; Krueger R; Price P; Leedman PJ
AIDS Res Hum Retroviruses; 2004 Feb; 20(2):157-62. PubMed ID: 15018703
[TBL] [Abstract][Full Text] [Related]
10. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
[TBL] [Abstract][Full Text] [Related]
11. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
12. Repeated presentation of Graves' disease as a manifestation of immune reconstitution syndrome in an HIV-infected patient taking HAART: case report.
Visković K; Stemberger L; Brnić Z; Begovac J
Acta Clin Croat; 2013 Mar; 52(1):125-7. PubMed ID: 23837283
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin receptor epitopes recognized by graves' autoantibodies developing under immunosuppressive therapy.
Wortsman J; McConnachie P; Tahara K; Kohn LD
J Clin Endocrinol Metab; 1998 Jul; 83(7):2302-8. PubMed ID: 9661599
[TBL] [Abstract][Full Text] [Related]
14. Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay.
Morgenthaler NG; Hodak K; Seissler J; Steinbrenner H; Pampel I; Gupta M; McGregor AM; Scherbaum WA; Banga JP
Thyroid; 1999 May; 9(5):466-75. PubMed ID: 10365678
[TBL] [Abstract][Full Text] [Related]
15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
16. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.
Khoo DH; Ho SC; Seah LL; Fong KS; Tai ES; Chee SP; Eng PH; Aw SE; Fok AC
Thyroid; 1999 Dec; 9(12):1175-80. PubMed ID: 10646655
[TBL] [Abstract][Full Text] [Related]
17. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal.
Guilhem I; Massart C; Poirier JY; Maugendre D
Thyroid; 2006 Oct; 16(10):1041-5. PubMed ID: 17042691
[TBL] [Abstract][Full Text] [Related]
18. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
[TBL] [Abstract][Full Text] [Related]
19. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
20. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
